Cargando…

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

BACKGROUND: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the antivascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niki, Maiko, Yokoi, Takashi, Kurata, Takayasu, Nomura, Shosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546813/ https://www.ncbi.nlm.nih.gov/pubmed/28814907 http://dx.doi.org/10.2147/LCTT.S138887

Ejemplares similares

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017)

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2017)

Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer
por: Nakaya, Aya, et al.
Publicado: (2017)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer
por: Nakaya, Aya, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report
por: Ogata, Makoto, et al.
Publicado: (2011)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

Microparticles as Biomarkers of Blood Coagulation in Cancer
por: Nomura, Shosaku, et al.
Publicado: (2015)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer
por: Yang, Jingru, et al.
Publicado: (2022)

Identification and validation of novel prognostic biomarkers and therapeutic targets for non-small cell lung cancer
por: Lai, Li-Ting, et al.
Publicado: (2023)

Combined small cell lung carcinoma and giant cell carcinoma: a case report
por: Saito, Tomohito, et al.
Publicado: (2017)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

Exosomal proteins as prognostic biomarkers in non‐small cell lung cancer
por: Sandfeld-Paulsen, B., et al.
Publicado: (2016)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris
por: Schell, Jonathan C., et al.
Publicado: (2011)

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Takagi, Yusuke, et al.
Publicado: (2013)

Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis
por: Yamanaka, Yuta, et al.
Publicado: (2019)

Antiplatelet antibody may cause delayed transfusion-related acute lung injury
por: Torii, Yoshitaro, et al.
Publicado: (2011)

Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics
por: Ozaki, Yoshio, et al.
Publicado: (2021)

Paraneoplastic Leukocytosis and Thrombocytosis as Prognostic Biomarkers in Non-small Cell Lung Cancer
por: BODDU, Prajwal, et al.
Publicado: (2016)

ARL14 as a Prognostic Biomarker in Non-Small Cell Lung Cancer
por: Zhang, Binbin, et al.
Publicado: (2021)

CDK7 is a prognostic biomarker for non-small cell lung cancer
por: Kuempers, Christiane, et al.
Publicado: (2022)

Prognostic biomarkers correlated with immune infiltration in non‐small cell lung cancer
por: Xu, Fei, et al.
Publicado: (2022)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
por: Martino, EC, et al.
Publicado: (2016)

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer
por: Xiao, Jie, et al.
Publicado: (2016)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
por: Ascha, Mustafa S., et al.
Publicado: (2019)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

The Significance of the Prognostic Nutritional Index in Patients with Completely Resected Non-Small Cell Lung Cancer
por: Mori, Shunsuke, et al.
Publicado: (2015)

Examination of biomarker expressions in sepsis-related DIC patients
por: Shimizu, Michiomi, et al.
Publicado: (2018)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR(+) non-small-cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2023)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2oeg089sp38r3u4sf021bje92n